Abbott Reports Third-Quarter 2017 Results

Go back to Abbott Reports Third-Quarter 2017 Results

Abbott Labs (ABT) PT Raised to $65 at Jefferies

October 19, 2017 9:25 AM EDT

Jefferies raised its price target on Abbott Labs (NYSE: ABT) to $65.00 (from $58.00) while maintaining a Buy rating following the company's 3Q earnings report. Org growth in 3Q of +5.6% was the best in 2 years and largely validates the recent portfolio moves. Driving the performance... More

Abbott Labs (ABT) PT Raised to $60 at Morgan Stanley

October 19, 2017 8:54 AM EDT

Morgan Stanley raised its price target on Abbott Labs (NYSE: ABT) to $60.00 (from $53.00) while maintaining a Equalweight rating.

... More

Abbott Labs (ABT) PT Raised to $63 at Stifel Following 3Q Release

October 18, 2017 5:06 PM EDT

Stifel raised its price target on Abbott Labs (NYSE: ABT) to $63.00 (from $58.00) while maintaining a Buy rating following the company's 3Q earnings report. The company reported above-expectation 5.6% comparable operational sales growth and above-consensus EPS at $0.66 (vs. $0.65 Consensus). positive 3Q highlights included: key product approvals, improving pipeline... More

UPDATE: Abbott (ABT) Tops Q3 EPS by 1c, Updates FY Guidance

October 18, 2017 7:46 AM EDT

(Updated - October 18, 2017 7:49 AM EDT)

Abbott (NYSE: ABT) reported Q3 EPS of $0.66, $0.01 better than the analyst estimate of $0.65. Revenue for the quarter came in at $6.83 billion versus the consensus estimate of $6.72 billion.

GUIDANCE:

Abbott narrowed its full-year... More